Which of these Neil Woodford dividend stocks should you buy today?

Roland Head takes a look at two of star fund manager Neil Woodford’s top income holdings.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With savings interest rates hitting new lows, interest in dividend stocks is stronger than ever.

In this article, I’ll compare the attractions of FTSE 100 income giants GlaxoSmithKline (LSE: GSK) and Legal & General Group (LSE: LGEN). Both companies are long-term favourites of star fund manager Neil Woodford, but which is the best choice for investors in search of a reliable income?

Positioned for growth?

Shares in GlaxoSmithKline have risen nearly 20% since the EU referendum caused the pound to plummet. While Glaxo’s trading is unlikely to be affected by Brexit, the firm reports its earnings in pounds. The weaker pound means that overseas earnings will be worth more than expected.  

In July’s interim results, Glaxo said that if exchange rates remained unchanged from the end of June, core earnings per share would rise by 19% this year. This is good news for dividend investors, as it should mean the firm’s 80p per share dividend will become more affordable.

However, currency tailwinds can rapidly reverse. I think it’s best to make sure a stock has other attractions before investing. The good news is that Glaxo’s investment in new products and restructuring is also starting to generate stronger profits.

Even before the referendum, City consensus forecasts for this year’s earnings had risen from 84p per share in December, to 88p in May. The latest forecasts are for earnings of 96.3p per share this year, rising to 101.6p in 2017.

Although analysts’ forecasts often lag events, my view is that the trend indicated by monthly changes is a useful guide to the performance of the underlying business. Consensus forecasts for Glaxo’s 2016 earnings have now risen every month since January. That’s a decent record.

Glaxo stock currently trades on 17 times forecast earnings and offers a prospective yield of 4.8%. I don’t think that’s cheap, but I agree with Neil Woodford’s view on the long-term growth potential of big pharmaceuticals businesses.

As a long-term income play, I think Glaxo remains a buy.

These shares could be oversold

Insurance and savings giant Legal & General is down by 21% so far this year, despite having bounced back from a post-referendum low of 160p.

The market remains bearish on Legal & General, despite the firm’s assurances that Brexit won’t affect its business. My view that the shares have probably been oversold was strengthened by the group’s recent interim results.

During the first half of 2016, Legal & General’s net cash generation — roughly equivalent to free cash flow — rose by 16% to £727m. Earnings per share rose by 24% to 11.27p, comfortably in line with full-year forecasts of 20.7p per share.

The dividend is expected to rise by 5.5% to 14.1p this year. This should be adequately covered by both net cash generation and earnings, so looks pretty safe to me.

Like GlaxoSmithKline, Legal & General should benefit from the world’s ageing populations and increasing levels of welfare spending. Its shares currently trade on just 10 times forecast earnings, and offer a prospective dividend yield of 6.8%. I believe decent gains could be possible from current levels, and also rate the stock as a buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline and Legal & General Group. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

I’d buy 1,784 shares of this FTSE 100 stock to target £350 of monthly passive income

Muhammad Cheema takes a look at how British American Tobacco shares, with a dividend yield of 10.1%, can generate a…

Read more »

White female supervisor working at an oil rig
Investing Articles

1 ex-FTSE 100 stock that I think will get promoted soon

Jon Smith flags up an energy stock that used to be in the FTSE 100 and currently has strong momentum…

Read more »

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

With an 8% dividend yield, I think this undervalued FTSE stock is a no-brainer buy

With an impressive yield and good track record of payments, Mark David Hartley is considering adding this promising FTSE share…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,500 in savings? Here’s how I’d try to turn that into £1,809 a month of passive income

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »